Palisade Bio, Inc. (PALI)
Oxford Ledge is still expanding full research coverage of PALI. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Pali Therapeutics develops targeted oral PDE4 inhibitors for inflammatory bowel disease using localized bacterial activation in the colon.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Departure/election of directors or officers; Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-06-11
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-12
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- DEF 14A Proxy statement for shareholder vote 2026-04-29
- 8-K Other material event 2026-04-02
Source: SEC EDGAR.
Annual results
5 years of annual figures for PALI, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $0 | -$16.8M | -$0.30 |
| 2024 | $0 | -$14.4M | -$10.19 |
| 2023 | — | -$12.3M | -$27.01 |
| 2022 | $0 | -$14.3M | -$16.53 |
| 2021 | — | -$26.6M | -$169.74 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for PALI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PALI in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.